×
ADVERTISEMENT

cutaneous T cell lymphoma

Brentuximab Vedotin Beats Standard of Care for CTCL

The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current ...

MARCH 15, 2017

Load more